FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases

SILVER SPRING, Md., Oct. 31, 2023 /PRNewswire/ — Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. Wezlana, like Stelara, is approved to treat the…

Leave a Reply

Your email address will not be published. Required fields are marked *